| Style | Citing Format |
|---|---|
| MLA | Danbaran GR, et al.. "Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594]." International Immunopharmacology, vol. , no. , 2025, pp. -. |
| APA | Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, Niaragh FJ, Babaie F, Mohammadi H (2025). Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594]. International Immunopharmacology, (), -. |
| Chicago | Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, Niaragh FJ, Babaie F, Mohammadi H. "Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594]." International Immunopharmacology , no. (2025): -. |
| Harvard | Danbaran GR et al. (2025) 'Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594]', International Immunopharmacology, (), pp. -. |
| Vancouver | Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, et al.. Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594]. International Immunopharmacology. 2025;():-. |
| BibTex | @article{ author = {Danbaran GR and Aslani S and Sharafkandi N and Hemmatzadeh M and Hosseinzadeh R and Azizi G and Niaragh FJ and Babaie F and Mohammadi H}, title = {Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594]}, journal = {International Immunopharmacology}, volume = {}, number = {}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Danbaran GR AU - Aslani S AU - Sharafkandi N AU - Hemmatzadeh M AU - Hosseinzadeh R AU - Azizi G AU - Niaragh FJ AU - Babaie F AU - Mohammadi H TI - Retraction Notice to “How Micrornas Affect the Pd-L1 and Its Synthetic Pathway in Cancer” [Int. Immunopharmacol. 84 (2020) 106594] JO - International Immunopharmacology VL - IS - SP - EP - PY - 2025 ER - |